ClinicalTrials.gg
CompletedNCT03502785Updated Sep 2, 2026Results posted

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

A Phase 1/2 interventional study of INO-5401 and INO-9012 in Urothelial Carcinoma, sponsored by Inovio Pharmaceuticals. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Inovio Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 360 studies in Carcinoma, Transitional Cell with a site in United States — 77 open to participants now, 140 under way, 14 of them phase 3. Carcinoma, Transitional Cell · United States.

Enrollment
198th of 333
35 · median 46
Started
2018
with 32 others
Phase 1/2
60 of 360
13 open now
Registered
135th of 360
by date

Among the 360 studies in Carcinoma, Transitional Cell with a site in United States, this one is the 198th largest by enrollment of the 333 interventional ones that give a count, is one of 33 that started in 2018, is one of 60 in phase 1/2, and was the 135th registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

77 of the 360 studies in Carcinoma, Transitional Cell with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 360 studies in Carcinoma, Transitional Cell with a site in United States, or all of them as a file.
02

Study summary

This was a Phase I/IIA, open-label, multi-center trial to evaluate the safety, immunogenicity and preliminary clinical efficacy of INO-5401 + INO-9012 delivered by intramuscular (IM) injection followed by electroporation (EP), in combination with atezolizumab in participants with locally advanced unresectable or metastatic/recurrent Urothelial Carcinoma (UCa). The trial population was divided into two cohorts: Cohort A: participants with locally advanced unresectable or metastatic/recurrent UCa, who had confirmed disease progression during or following treatment with anti-programmed death receptor-1/programmed death receptor ligand-1 (anti-PD-1/PD-L1) therapy; Cohort B: participants with locally advanced unresectable or metastatic/recurrent UCa, who were treatment naïve and ineligible for cisplatin-based chemotherapy. A safety run-in was performed using a modified rolling six design, enrolling up to 6 participants (safety analysis participants) from Cohort A.

03

Conditions studied

  • Urothelial Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign an Form (ICF);
  • Have or cytologically documented locally advanced unresectable or /recurrent urothelial carcinoma (including renal pelvis, ureters, urinary bladder, and urethra);
  • For Cohort A: Participants who have radiographically confirmed disease progression during or following treatment with an /PD-L1 based therapy;
  • For Cohort B: No prior chemotherapy for inoperable locally advanced or metastatic or recurrent UCa and ineligible ("unfit") for cisplatin-based chemotherapy;
  • Have , as defined by (RECIST) version 1.1;
  • Have a performance status of 0 or 1 on (ECOG) Performance Scale;
  • Have of >/= 3 months;
  • Be willing to provide a tissue sample for pre-treatment intra-tumoral assessment of proinflammatory and factors;
  • Have (ECG) with no findings as assessed by the investigator performed within 28 days prior to first dose;
  • Demonstrate adequate hematological, renal, hepatic, and coagulation function;
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use methods that result in a failure rate of \< 1% per year during the treatment period and for at least 5 months after the last dose of study treatment;
  • For male participants: agreement not to father a child. Participants must be surgically sterile (e.g, vasectomy) or use contraceptive methods that result in a failure rate of \< 1% per year during the treatment period and for at least 5 months after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Any approved anti-cancer therapy including chemotherapy, targeted small molecule therapy or radiation therapy within 2 weeks prior to trial Day 0 as well as current participation or recipient of treatment on a clinical trial within 28 days prior to Day 0;
  • Documented active or untreated central nervous system (CNS) and/or carcinomatous meningitis;
  • other than UCa within 3 years prior to Day 0, with the exception of those with negligible risk of metastasis or death treated with expected curative outcome;
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies;
  • Treatment with systemic immunostimulatory agents;
  • Treatment with systemic medication;
  • History of severe allergic, anaphylactic, or other reactions to chimeric or humanized antibodies or fusion proteins;
  • Known hypersensitivity allergy or to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the /PD-L1 inhibitor formulation;
  • Active or history of disease or immune deficiency;
  • History or any evidence of interstitial lung disease;
  • History of (HIV);
  • Active or active ;
  • Severe infections within 4 weeks prior to enrollment;
  • Received therapeutic oral or IV antibiotics within 2 weeks prior to Day 0;
  • History or current evidence of any condition, therapy or laboratory abnormality that might confound the results of the trial; interfere with the participant's participation for the full duration of the trial, or is negatively impacted by EP treatment, or is not in the best interest of the participant to participate in the opinion of the treating investigator;
  • Prior allogeneic stem cell or solid organ transplant;
  • Uncontrolled tumor-related pain; pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures; or, hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Cohort A: Prior Anti-PD-1/PD-L1

    Participants with locally advanced unresectable or metastatic/recurrent UCa, who had confirmed disease progression during or following treatment with anti- programmed death receptor-1/ programmed cell death-ligand 1 (PD-1/PD-L1) therapy received INO-5401 9 milligrams (mg) and INO-9012 1 mg, intramuscular (IM) injection, followed by electroporation (EP) by CELLECTRA® 2000 device, every 3 weeks until Week 9, then every 6 weeks for 6 more doses (until Week 45), thereafter every 12 weeks, until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator in combination with atezolizumab 1200 mg, intravenous (IV) infusion, every 3 weeks, until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator.

    Biological: INO-5401 · Biological: INO-9012 · Drug: Atezolizumab · Device: CELLECTRA® 2000

  • Experimental
    Cohort B: Naïve Anti-PD-1/PD-L1

    Participants with locally advanced unresectable or metastatic/recurrent UCa who are treatment naïve and ineligible for cisplatin-based chemotherapy received INO-5401 9 mg and INO-9012 1 mg, IM injection, followed by EP by CELLECTRA® 2000 device, every 3 weeks until Week 9, then every 6 weeks for 6 more doses (until Week 45), thereafter every 12 weeks, until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator in combination with atezolizumab 1200 mg, IV infusion, every 3 weeks, until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator.

    Biological: INO-5401 · Biological: INO-9012 · Drug: Atezolizumab · Device: CELLECTRA® 2000

Interventions

  • BiologicalINO-5401

    INO-5401: A mixture of 3 synthetic plasmids that target Wilms' tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) antigen. IM injection

  • BiologicalINO-9012

    INO-9012: A synthetic plasmid that expresses human interleukin-12 (IL-12). IM injection.

  • IV-Infusion.

  • DeviceCELLECTRA® 2000

    IM injection.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs) Treatment

    An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as any AEs that occurred on or after Day 0. AESIs were toxicities and immune-mediated AEs that may have occurred up to 90 days after the last dose of trial treatment. AESIs were reported by the investigator to the Sponsor within 24 hours after learning of the event.

    Time frame: Up to approximately 71 months

  2. Number of Participants With Clinically Significant Changes in Hematological Parameters

    Clinically significant changes in hematological parameters were determined based on the investigator's discretion.

    Time frame: Up to approximately 71 months

  3. Number of Participants With Clinically Significant Changes in Serum Chemistry Parameters

    Clinically significant changes in serum chemistry parameters were determined based on the investigator's discretion.

    Time frame: Up to approximately 71 months

  4. Number of Participants With Clinically Significant Changes in Urinalysis Parameters

    Clinically significant changes in urinalysis parameters were determined based on the investigator's discretion.

    Time frame: At baseline, Weeks 3, 6, 9, then every 6 weeks thereafter, up to 71 months

  5. Antigen-Specific Immune Response

    Blood and tissue samples were collected to evaluate the antigen-specific immune response to INO-5401 + INO-9012 in combination with atezolizumab. Planned assessments included: Enzyme Linked Immunosorbent Spot-forming (ELISpot) Assay, Flow cytometry, T cell receptor (TCR) sequencing, ELISA and/or gene expression analysis.

    Time frame: Up to approximately 71 months

  6. Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Review in Cohort A

    ORR was defined as the percentage of participants who had a confirmed complete response (CR) or a partial response (PR). CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters) per RECIST 1.1.

    Time frame: From date of treatment start until date of first PD or death (whichever occurred first), up to approximately 71 months

Secondary outcomes

  1. ORR as Assessed by RECIST Version 1.1 by Investigator Review in Cohort B

    ORR was defined as the percentage of participants who had a confirmed CR or a PR. CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters) per RECIST 1.1.

    Time frame: From date of treatment start until date of first PD or death (whichever occurred first), up to approximately 71 months

  2. Percentage of Participants With ORR by Immune Response Evaluation Criteria in Solid Tumors (iRECIST)

    ORR was defined as the percentage of participants who had a confirmed CR or a PR. CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters) per iRECIST.

    Time frame: From date of treatment start until date of first PD or death (whichever occurred first), up to approximately 71 months

  3. Duration of Response (DoR)

    DOR was defined as the time from the date of the first PR or CR to the date of death from any cause or date that progressive disease (PD) was objectively documented, whichever occurred first. CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters). PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on trial (nadir), including baseline. The sum also had to demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.

    Time frame: From first documented confirmed CR or PR until first documentation of PD or death, whichever occurred first (approximately 71 months)

  4. Progression-Free Survival (PFS) Per RECIST Version 1.1

    PFS was defined as the time from the date of the start of investigational product treatment until the date of death from any cause or date that progression (+1 day) was objectively documented, whichever occurred first as assessed by RECIST Version 1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on trial (nadir), including baseline. The sum also had to demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.

    Time frame: From the first dose of study drug to date of PD or death, whichever occurred first (up to approximately 71 months)

  5. PFS Per Immune RECIST (iRECIST)

    PFS was defined as the time from the date of the start of investigational product treatment until the date of death from any cause or date that progression (+1 day) was objectively documented, whichever occurred first as assessed by iRECIST Version 1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on trial (nadir), including baseline. The sum also had to demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.

    Time frame: From Baseline to disease progression or death, whichever occurs first (up to approximately 71 months)

  6. Overall Survival (OS)

    OS was defined as the time from the date of the start of investigational product treatment until the date of death from any cause.

    Time frame: From date of first dose of study drug up to death from any cause, (approximately 71 months)

07

Results

Posted Sep 2, 2026

Participant flow

Participants took part at the investigative sites from 24 July 2018 to 09 May 2025.

Participant flow — Overall Study
MilestoneCohort A: Prior Anti-PD-1/PD-L1Cohort B: Naïve Anti-PD-1/PD L1
Started278
Completed00
Not completed278
Withdrew: Adverse event31
Withdrew: Physician decision01
Withdrew: Withdrawal by subject10
Withdrew: Progressive disease94
Withdrew: Death141
Withdrew: Reason unspecified01

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs) Treatment

An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as any AEs that occurred on or after Day 0. AESIs were toxicities and immune-mediated AEs that may have occurred up to 90 days after the last dose of trial treatment. AESIs were reported by the investigator to the Sponsor within 24 hours after learning of the event.

Time frame:
Up to approximately 71 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs) Treatment
ParticipantsCohort A: Prior Anti-PD-1/PD-L1Cohort B: Naïve Anti-PD-1/PD-L1
Participants with TEAEs278
Participants with AESIs20
PrimaryNumber of Participants With Clinically Significant Changes in Hematological Parameters

Clinically significant changes in hematological parameters were determined based on the investigator's discretion.

Time frame:
Up to approximately 71 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Hematological Parameters
ParticipantsCohort A: Prior Anti-PD-1/PD-L1Cohort B: Naïve Anti-PD-1/PD-L1
Number of Participants With Clinically Significant Changes in Hematological Parameters00
PrimaryNumber of Participants With Clinically Significant Changes in Serum Chemistry Parameters

Clinically significant changes in serum chemistry parameters were determined based on the investigator's discretion.

Time frame:
Up to approximately 71 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Serum Chemistry Parameters
ParticipantsCohort A: Prior Anti-PD-1/PD-L1Cohort B: Naïve Anti-PD-1/PD-L1
Number of Participants With Clinically Significant Changes in Serum Chemistry Parameters00
PrimaryNumber of Participants With Clinically Significant Changes in Urinalysis Parameters

Clinically significant changes in urinalysis parameters were determined based on the investigator's discretion.

Time frame:
At baseline, Weeks 3, 6, 9, then every 6 weeks thereafter, up to 71 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Urinalysis Parameters
ParticipantsCohort A: Prior Anti-PD-1/PD-L1Cohort B: Naïve Anti-PD-1/PD-L1
Number of Participants With Clinically Significant Changes in Urinalysis Parameters00
PrimaryAntigen-Specific Immune Response

Blood and tissue samples were collected to evaluate the antigen-specific immune response to INO-5401 + INO-9012 in combination with atezolizumab. Planned assessments included: Enzyme Linked Immunosorbent Spot-forming (ELISpot) Assay, Flow cytometry, T cell receptor (TCR) sequencing, ELISA and/or gene expression analysis.

Time frame:
Up to approximately 71 months

No measurements were reported for this outcome.

PrimaryObjective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Review in Cohort A

ORR was defined as the percentage of participants who had a confirmed complete response (CR) or a partial response (PR). CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters) per RECIST 1.1.

Time frame:
From date of treatment start until date of first PD or death (whichever occurred first), up to approximately 71 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Review in Cohort A
Percentage of participantsCohort A: Prior Anti-PD-1/PD-L1
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Review in Cohort A0
SecondaryORR as Assessed by RECIST Version 1.1 by Investigator Review in Cohort B

ORR was defined as the percentage of participants who had a confirmed CR or a PR. CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters) per RECIST 1.1.

Time frame:
From date of treatment start until date of first PD or death (whichever occurred first), up to approximately 71 months
Reported as:
Number · Percentage of participants
ORR as Assessed by RECIST Version 1.1 by Investigator Review in Cohort B
Percentage of participantsCohort B: Naïve Anti-PD-1/PD-L1
ORR as Assessed by RECIST Version 1.1 by Investigator Review in Cohort B40
SecondaryPercentage of Participants With ORR by Immune Response Evaluation Criteria in Solid Tumors (iRECIST)

ORR was defined as the percentage of participants who had a confirmed CR or a PR. CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters) per iRECIST.

Time frame:
From date of treatment start until date of first PD or death (whichever occurred first), up to approximately 71 months
Reported as:
Number · Percentage of participants
Percentage of Participants With ORR by Immune Response Evaluation Criteria in Solid Tumors (iRECIST)
Percentage of participantsCohort A: Prior Anti-PD-1/PD-L1Cohort B: Naïve Anti-PD-1/PD-L1
Percentage of Participants With ORR by Immune Response Evaluation Criteria in Solid Tumors (iRECIST)040
SecondaryDuration of Response (DoR)

DOR was defined as the time from the date of the first PR or CR to the date of death from any cause or date that progressive disease (PD) was objectively documented, whichever occurred first. CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters). PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on trial (nadir), including baseline. The sum also had to demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.

Time frame:
From first documented confirmed CR or PR until first documentation of PD or death, whichever occurred first (approximately 71 months)
Reported as:
Median · months
Duration of Response (DoR)
monthsCohort A: Prior Anti-PD-1/PD-L1Cohort B: Naïve Anti-PD-1/PD-L1
Duration of Response (DoR)—NA (NA to NA)
SecondaryProgression-Free Survival (PFS) Per RECIST Version 1.1

PFS was defined as the time from the date of the start of investigational product treatment until the date of death from any cause or date that progression (+1 day) was objectively documented, whichever occurred first as assessed by RECIST Version 1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on trial (nadir), including baseline. The sum also had to demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.

Time frame:
From the first dose of study drug to date of PD or death, whichever occurred first (up to approximately 71 months)
Reported as:
Median · months
Progression-Free Survival (PFS) Per RECIST Version 1.1
monthsCohort A: Prior Anti-PD-1/PD-L1Cohort B: Naïve Anti-PD-1/PD-L1
Progression-Free Survival (PFS) Per RECIST Version 1.1NA (NA to NA)NA (NA to NA)
SecondaryPFS Per Immune RECIST (iRECIST)

PFS was defined as the time from the date of the start of investigational product treatment until the date of death from any cause or date that progression (+1 day) was objectively documented, whichever occurred first as assessed by iRECIST Version 1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on trial (nadir), including baseline. The sum also had to demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.

Time frame:
From Baseline to disease progression or death, whichever occurs first (up to approximately 71 months)
Reported as:
Median · months
PFS Per Immune RECIST (iRECIST)
monthsCohort A: Prior Anti-PD-1/PD-L1Cohort B: Naïve Anti-PD-1/PD-L1
PFS Per Immune RECIST (iRECIST)NA (NA to NA)NA (NA to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of the start of investigational product treatment until the date of death from any cause.

Time frame:
From date of first dose of study drug up to death from any cause, (approximately 71 months)
Reported as:
Median · months
Overall Survival (OS)
monthsCohort A: Prior Anti-PD-1/PD-L1Cohort B: Naïve Anti-PD-1/PD-L1
Overall Survival (OS)NA (NA to NA)NA (NA to NA)

Adverse events

Collected over Up to approximately 71 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A15/27 (55.6%)8/27 (29.6%)27/27 (100%)
Cohort B1/8 (12.5%)3/8 (37.5%)8/8 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventCohort ACohort B
AnaemiaBlood and lymphatic system disorders0/271/8
Inappropriate antidiuretic hormone secretionEndocrine disorders0/271/8
Urostomy complicationInjury, poisoning and procedural complications0/271/8
Demyelinating polyneuropathyNervous system disorders0/271/8
Mental status changesPsychiatric disorders0/271/8
Pelvic painReproductive system and breast disorders0/271/8
Abdominal painGastrointestinal disorders1/270/8
ConstipationGastrointestinal disorders1/270/8
EnteritisGastrointestinal disorders1/270/8
Clostridium difficile colitisInfections and infestations1/270/8
Most frequent other events
Showing 10 of 49
Most frequent other events
EventCohort ACohort B
FatigueGeneral disorders7/274/8
NauseaGastrointestinal disorders12/270/8
Back painMusculoskeletal and connective tissue disorders7/273/8
Rash maculo-papularSkin and subcutaneous tissue disorders1/273/8
HypertensionVascular disorders3/273/8
DiarrhoeaGastrointestinal disorders7/270/8
HeadacheNervous system disorders7/270/8
AnaemiaBlood and lymphatic system disorders2/272/8
Sinus tachycardiaCardiac disorders1/272/8
PyrexiaGeneral disorders3/272/8

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort A: Prior Anti-PD-1/PD-L1Cohort B: Naïve Anti-PD-1/PD-L1Total
Mean68.6 ± 8.0065.0 ± 13.0067.7 ± 9.27
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: Prior Anti-PD-1/PD-L1Cohort B: Naïve Anti-PD-1/PD-L1Total
Female12315
Male15520
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A: Prior Anti-PD-1/PD-L1Cohort B: Naïve Anti-PD-1/PD-L1Total
Hispanic or Latino101
Not Hispanic or Latino26834
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A: Prior Anti-PD-1/PD-L1Cohort B: Naïve Anti-PD-1/PD-L1Total
American Indian or Alaska Native000
Asian202
Native Hawaiian or Other Pacific Islander000
Black or African American303
White22830
More than one race000
Unknown or Not Reported000
08

Study locations

11 sites
  • Mayo Clinic Cancer Center
    Phoenix, Arizona 85054, United States
  • H. Lee Moffitt Cancer Center & Research Institute, Inc.
    Tampa, Florida 33612, United States
  • Johns Hopkins University School of Medicine
    Baltimore, Maryland 21287, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Washington University School of Medicine in St. Louis
    St Louis, Missouri 63110, United States
  • New York University Langone Medical Center - Perlmutter Cancer Center
    New York, New York 10016, United States
  • Columbia University, Herbert Irving Comprehensive Cancer Center
    New York, New York 10032, United States
  • University of North Carolina School of Medicine
    Chapel Hill, North Carolina 27599, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • Greenville Memorial Hospital
    Greenville, South Carolina 29615, United States
  • Inova Melanoma and Skin Cancer Center
    Fairfax, Virginia 22031, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in May 2025, 81 months.

Results were first posted in Sep 2026, 1 year 3 months after primary completion.

Of 47 phase 1/2 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 224. This study's 81 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2018
First posted
Apr 19, 2018
StartActual
Jul 24, 2018
Primary completionActual
May 9, 2025
CompletionActual
May 9, 2025
Results first posted
Sep 2, 2026
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03502785
Responsible party
Sponsor
First posted
Apr 19, 2018
Start date
Jul 24, 2018
Primary completion
May 9, 2025
Completion
May 9, 2025
Results posted
Sep 2, 2026
Last update
Sep 2, 2026

Study contacts

Jeffrey Skolnik, MD
study director · Inovio Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401 · Rocakinogene sifuplasmid

Start the discussion